Natalie Sacks, M.D.
Natalie Sacks, M.D.
Natalie Sacks, M.D., is an oncologist and drug developer with more than 20 years of experience in the biotechnology industry. She currently serves as a Venture Partner in the Venture Investments group at Novo Holdings, a global life science investment firm.
Prior to joining Novo Holdings Venture Investments, Dr. Sacks served as the Chief Medical Officer at Harpoon Therapeutics (acquired by Merck). Earlier, she held various development and executive roles at multiple companies including Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. Dr. Sacks’ expertise includes all aspects of development ranging from initial IND to the late-stage development of commercially available oncology therapeutics.
In addition to her roles in biotech, Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. Dr. Sacks holds a B.A. in Mathematics from Bryn Mawr College, an M.S. in Biostatistics from the Harvard University School of Public Health, and an M.D. from the University of Pennsylvania School of Medicine.